XML 62 R5.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash flows from operating activities:    
Net (loss)/income $ (2,738,542) $ 369,416,894
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and other amortization 395,540 48,639
(Decrease)/increase in fair value of warrant liability (4,774,711) 5,271,503
Stock-based compensation 1,717,380 1,866,279
Deferred income taxes provision benefit (1,065,675) (25,520,615)
Net realization of deferred revenue and costs due to FDA approval 0 (281,950,853)
Non-cash interest expense 3,363,712 3,363,712
Changes in assets and liabilities:    
Accounts receivable (1,258,568) 369,872
Inventory (1,022,951) 0
Prepaid expenses and other assets 2,189,076 567,042
Accounts payable, accrued expenses and other liabilities (697,325) (969,951)
Deferred revenue (47,939) 0
Net cash (used in)/provided by operating activities (3,940,003) 72,462,522
Cash flows from investing activities:    
Capital expenditures (29,092) (27,863)
Net cash used in investing activities (29,092) (27,863)
Cash flows from financing activities:    
Net proceeds from exercise of stock options 0 252,679
Payment of employee tax obligations for common stock tendered (199,810) (1,708,290)
Net cash used in financing activities (199,810) (1,455,611)
Net (decrease)/increase in cash, cash equivalents and restricted cash (4,168,905) 70,979,048
Cash, cash equivalents and restricted cash at the beginning of period 180,396,910 37,101,586
Cash, cash equivalents and restricted cash at end of period 176,228,005 108,080,634
Supplemental disclosure of non-cash financing activities:    
Conversion of warrants to common stock 1,172,801 6,007,847
Issuance of common stock upon cashless exercise $ 118,500 $ 1,582,420